KSC Healthcare Biotechnology 207940.KS

Samsung Biologics Co.,Ltd.

$ 1 374 000.00 -3.92 %

Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.

CEO: John Chongbo Rim - https://samsungbiologics.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ -4 049 574.64

Loading data...

207940.KS vs S&P500

Loading data...

No data available.

Quick ratio

0.86

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

0.00

may indicate that the company is undervalued or has poor growth prospects.

EPS

0.00

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

19.19 %

reflects reasonable profitability, showing good use of equity.

ROIC

14.77 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.16

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.15

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

31 554.59

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
11.43 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.19 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.10 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.